Aldeyra Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-03-02$5.62 RISE2026-04-29$1.50 PEAK2026-05-26$1.78 85d | -73.3% 58d | Missed | Missed | — | — | +18.7% 27d | Missed |
DROP2026-03-02$5.62 RISE2026-03-17$1.24 PEAK2026-03-23$2.23 21d | -77.9% 15d | Missed | Missed | — | — | +79.8% 6d | Missed |
DROP2025-08-26$5.89 RISE2025-12-15$3.99 PEAK2026-03-02$5.62 188d | -32.3% 111d | Missed | Missed | — | — | +40.9% 77d | Missed |
DROP2025-08-26$5.89 RISE2025-11-07$4.69 PEAK2025-11-26$5.59 92d | -20.4% 73d | Missed | Missed | — | — | +19.2% 19d | Missed |
DROP2025-08-26$5.89 RISE2025-09-17$4.90 PEAK2025-10-03$5.74 38d | -16.8% 22d | Missed | Missed | — | — | +17.1% 16d | Missed |
DROP2025-03-12$6.98 RISE2025-04-03$1.42 PEAK2025-07-01$3.93 111d | -79.7% 22d | Missed | Missed | — | — | +176.8% 89d | Missed |
DROP2025-02-19$6.78 RISE2025-02-28$5.11 PEAK2025-03-12$6.98 21d | -24.6% 9d | Missed | Missed | — | — | +36.6% 12d | Missed |
DROP2024-09-05$6.32 RISE2025-01-14$4.70 PEAK2025-03-12$6.98 188d | -25.6% 131d | Missed | Missed | — | — | +48.5% 57d | Missed |
DROP2024-09-05$6.32 RISE2024-11-15$4.21 PEAK2025-02-14$6.49 162d | -33.4% 71d | Missed | Missed | — | — | +54.2% 91d | Missed |
DROP2024-04-05$4.72 RISE2024-08-05$3.23 PEAK2024-09-04$6.32 152d | -31.7% 122d | Missed | Missed | — | — | +96.0% 30d | Missed |
DROP2024-04-05$4.72 RISE2024-07-05$3.19 PEAK2024-09-04$6.32 152d | -32.4% 91d | Missed | Missed | — | — | +98.1% 61d | Missed |
DROP2024-04-05$4.72 RISE2024-05-13$3.70 PEAK2024-07-16$4.30 102d | -21.6% 38d | Missed | Missed | — | — | +16.2% 64d | Missed |
DROP2024-03-01$4.22 RISE2024-03-14$2.77 PEAK2024-04-05$4.72 35d | -34.4% 13d | Missed | Missed | — | — | +70.4% 22d | Missed |
DROP2023-09-14$6.96 RISE2024-01-24$3.00 PEAK2024-04-05$4.72 204d | -56.9% 132d | Missed | Missed | — | — | +57.3% 72d | Missed |
DROP2023-06-30$8.39 RISE2023-10-27$1.47 PEAK2023-12-27$3.63 180d | -82.5% 119d | Missed | Missed | — | — | +146.9% 61d | Missed |
1–15 / 29 1 / 2 | |||||||
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims agains...
Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In this context of robust market performance, identifying stocks that are trading below their fair value can be a strategic move for investors seeking opportunities for potential growth and value.
Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In this context of robust market performance, identifying stocks that are trading below their fair value can be a strategic move for investors seeking opportunities for potential growth and value.
Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying stocks that may be undervalued can present opportunities for investors seeking potential value plays amidst strong market performance.
Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying stocks that may be undervalued can present opportunities for investors seeking potential value plays amidst strong market performance.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims agains...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims agains...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims agains...
NEW YORK, May 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against...
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against...
In the last week, the United States market has stayed flat, yet it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that are potentially undervalued can present opportunities for investors looking to capitalize on discrepancies between stock prices and their intrinsic values.
In the last week, the United States market has stayed flat, yet it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that are potentially undervalued can present opportunities for investors looking to capitalize on discrepancies between stock prices and their intrinsic values.
In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.
In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.
The United States market has remained flat over the last week but has seen a significant rise of 29% over the past 12 months, with earnings forecasted to grow by 16% annually. In this context, identifying stocks that are trading below their intrinsic value can present compelling opportunities for investors seeking to capitalize on potential growth while navigating current market conditions.
The United States market has remained flat over the last week but has seen a significant rise of 29% over the past 12 months, with earnings forecasted to grow by 16% annually. In this context, identifying stocks that are trading below their intrinsic value can present compelling opportunities for investors seeking to capitalize on potential growth while navigating current market conditions.
Over the last 7 days, the United States market has remained flat, yet over the past 12 months, it has risen by an impressive 29%, with earnings forecasted to grow by 16% annually. In these conditions, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALDX | +10.06% | -68.86% | -66.22% | -18.60% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +7.09% | -63.15% | -62.77% | -31.29% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| DEShaw | quant | 1.40M | $2.37M | 0.00% | Trimmed-12.3% | 2026-03-31 |
| StateStreet | passive | 1.12M | $1.90M | 0.00% | Added+2.4% | 2026-03-31 |
| RenTech | quant | 863.2K | $1.46M | 0.00% | Added+146.6% | 2026-03-31 |
| TwoSigma | quant | 223.5K | $377.78K | 0.00% | Trimmed-22.2% | 2026-03-31 |
| Wellington | fundamental | 149.0K | $251.75K | 0.00% | Trimmed-16.7% | 2026-03-31 |
| FidelityFMR | fundamental | 16.5K | $27.89K | 0.00% | Added+136.9% | 2026-03-31 |
| TRowePrice | fundamental | 73.8K | $125 | 0.00% | Added+14.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.09 | — | — |
| 2026-05-07 | -0.12 | -0.06 | +50.00% |
| 2026-02-27 | 0.16 | -0.10 | -163.16% |
| 2025-11-05 | -0.16 | -0.13 | +17.46% |
| 2025-08-07 | -0.19 | -0.16 | +14.67% |
| 2025-05-14 | -0.28 | -0.17 | +39.29% |
| 2025-02-28 | -0.22 | -0.27 | -24.25% |
| 2024-11-07 | -0.26 | -0.25 | +3.64% |
| 2024-08-01 | -0.14 | -0.28 | -97.94% |
| 2024-05-02 | -0.11 | -0.14 | -32.29% |
| 2024-03-07 | -0.12 | -0.08 | +35.80% |
| 2023-11-03 | -0.25 | -0.14 | +43.11% |
| 2023-08-03 | -0.30 | -0.15 | +50.28% |
| 2023-05-04 | -0.28 | -0.27 | +3.77% |
| 2023-03-09 | -0.30 | -0.22 | +25.73% |
| 2022-11-10 | -0.31 | -0.25 | +19.87% |